Claims
- 1. A method of treating macular degeneration in an individual, comprising the step of increasing reverse cholesterol transport in an ocular tissue of the individual.
- 2. The method of claim 1, wherein said increasing reverse cholesterol transport comprises delivering to the individual a ligand of a nuclear hormone receptor, a lipid transporter, or both.
- 3. The method of claim 2, wherein the lipid transporter is HDL, prebeta-HDL, HDL1, HDL2, HDL3, prebeta-1, prebeta-2, prebeta-3, prebeta 4 HDL, or a mixture thereof.
- 4. The method of claim 2, wherein said ligand of a nuclear hormone receptor is T3, TRIAC (3-triiodothyroacetic acid), GC-1, KB141, 3,5 dimethyl-3-isopropylthyronine, 22 (R) hydroxycholesterol, acetyl-podocarpic dimer, T0901317, GW3965 (12), 24(S),25-epoxycholesterol, 24(R),25-epoxycholesterol, 22(R)-ol-24(S),25-epoxycholesterol, 22(S)-ol,24(R),25-epoxycholesterol, 24(S),25-iminocholesterol, methyl-H-cholenate, dimethylhydroxycholenamide, 24(S)-hydroxycholesterol, 24(R)-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R),24(S)-dihydroxycholesterol, 25-hydroxycholesterol, 24(S),25-dihydroxycholesterol, 24(R),25-dihydroxycholesterol, 24,25-dehydrocholesterol, 7(α)-ol,24(S),25-epoxycholesterol, 7(β)-ol, 24(S),25-epoxycholesterol, 7k,24(S),25-epoxycholesterol, 7(α)-hydroxycholesterol, 7-ketocholesterol, cholesterol, 5,6-24(S),25-diepoxycholesterol, 9 cis-retinoic acid, AGN 191659 [(E)-5-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)propen-1-yl]-2-thiophenecarboxylic acid], AGN 191701 [(E) 2-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)propen-1-yl]-4-thiophene-carboxylic acid], AGN 192849 [(3,5,5,8,8,-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl) (5 carboxypyrid-2-yl)sulfide], LGD346, LG100268, LG100754, BMS649, bexaroteneR (4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl) ethenyl] benzoic acid), or a mixture thereof.
- 5. A method of preventing and/or reducing lipid accumulation in an ocular tissue, comprising the step of increasing the level of a lipid transporter in said tissue.
- 6. The method of claim 5, wherein said increasing the level of the lipid transporter comprises delivering said lipid transporter to the tissue.
- 7. The method of claim 5, wherein said lipid transporter is HDL or a subspecies thereof.
- 8. The method of claim 5, wherein said ocular tissue is retinal pigment epithelium (RPE), Bruch's membrane, choriocapillaris, or a combination thereof.
- 9. The method of claim 7, wherein said subspecies of HDL is prebeta-HDL, HDL1, HDL2, HDL3, prebeta-1, prebeta-2, prebeta-3, and/or prebeta-4 HDL.
- 10. The method of claim 7, wherein said HDL or subspecies thereof further comprises apo E.
- 11. The method of claim 5, wherein said ocular tissue is comprised in an individual.
- 12. The method of claim 11, wherein said individual is afflicted with macular degeneration.
- 13. The method of claim 12, wherein said macular degeneration is age-related macular degeneration.
- 14. The method of claim 11, wherein said individual is afflicted with Stargardts disease (fundus flavimaculatus).
- 15. A method of increasing lipid efflux from an ocular tissue comprising the step of increasing the level of at least one lipid transporter in said tissue.
- 16. The method of claim 15, wherein said lipid transporter is HDL or a subspecies thereof.
- 17. The method of claim 15, wherein said increasing the level step is further defined as delivering the lipid transporter to the tissue.
- 18. A method of treating macular degeneration (AMD) in an individual, comprising the step of delivering a therapeutically effective amount of at least one lipid transporter to at least one tissue of the individual.
- 19. The method of claim 18, wherein said lipid transporter is HDL or a subspecies thereof.
- 20. The method of claim 18, wherein said tissue is retinal pigment epithelium (RPE), Bruch's membrane, choriocapillaris, or a combination thereof.
- 21. The method of claim 19, wherein said subspecies of HDL is prebeta-HDL, HDL1, HDL2, HDL3, prebeta-1, prebeta-2, prebeta-3, and/or prebeta 4 HDL.
- 22. The method of claim 19, wherein said HDL or subspecies thereof further comprises apo E.
- 23. A kit for the prevention or treatment of macular degeneration, housed in a suitable container, comprising a lipid transporter.
- 24. The kit of claim 23, wherein said lipid transporter is HDL or a subspecies thereof.
- 25. The kit of claim 24, wherein said subspecies of HDL is preb-HDL, HDL1, HDL2, HDL3, prebeta-1, prebeta-2, prebeta-3, and/or prebeta 4 HDL.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present invention claims priority to U.S. Nonprovisional Patent Application No. 10/313,641, filed Dec. 6, 2002; U.S. Provisional Patent Application No. 60/340,498, filed Dec. 7, 2001; and U.S. Provisional Patent Application No. 60/415,864, filed Oct. 3, 2002, all of which are incorporated by reference herein in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60340498 |
Dec 2001 |
US |
|
60415864 |
Oct 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10313641 |
Dec 2002 |
US |
Child |
10428551 |
May 2003 |
US |